Travere Therapeutics, Inc.
TVTX
$28.32
$0.521.87%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 129.69M | 164.86M | 114.45M | 81.73M | 74.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 129.69M | 164.86M | 114.45M | 81.73M | 74.79M |
| Cost of Revenue | 60.42M | 53.48M | 50.88M | 51.57M | 64.62M |
| Gross Profit | 69.27M | 111.38M | 63.57M | 30.16M | 10.17M |
| SG&A Expenses | 101.69M | 86.45M | 76.22M | 72.84M | 69.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 162.12M | 139.93M | 127.10M | 124.41M | 134.12M |
| Operating Income | -32.43M | 24.93M | -12.65M | -42.67M | -59.33M |
| Income Before Tax | -21.07M | 25.71M | -12.74M | -41.19M | -60.34M |
| Income Tax Expenses | 921.00K | 8.00K | 20.00K | 39.00K | -72.00K |
| Earnings from Continuing Operations | -21.99M | 25.71M | -12.76M | -41.23M | -60.27M |
| Earnings from Discontinued Operations | 24.72M | -- | -- | -- | 4.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.73M | 25.71M | -12.76M | -41.23M | -60.26M |
| EBIT | -32.43M | 24.93M | -12.65M | -42.67M | -59.33M |
| EBITDA | -14.29M | 40.72M | 1.37M | -29.87M | -47.24M |
| EPS Basic | 0.03 | 0.29 | -0.14 | -0.47 | -0.73 |
| Normalized Basic EPS | -0.15 | 0.18 | -0.09 | -0.29 | -0.44 |
| EPS Diluted | 0.03 | 0.28 | -0.14 | -0.47 | -0.73 |
| Normalized Diluted EPS | -0.15 | 0.16 | -0.09 | -0.29 | -0.44 |
| Average Basic Shares Outstanding | 90.29M | 89.23M | 88.95M | 88.36M | 83.11M |
| Average Diluted Shares Outstanding | 90.29M | 102.62M | 88.95M | 88.36M | 83.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |